ROS1 and non-small cell lung carcinoma: In conclusion, these data support the clinical applicability of liquid biopsies to inform clinical decisions, and provide further evidence that entrectinib is effective and well tolerated in patients with ROS1-positive, advanced/metastatic NSCLC.